#1
Source: Annals of Oncology | Authors: Chen YX, Jin Y, ... Xu RH, Wang ZX, Wang F (Sun Yat-Sen University Cancer Center) — multicenter, China | Published: Ann Oncol 2026;37(7):986–998
Score: 13/20 — Base 7 (Annals of Oncology, Tier-1) + Phase III RCT (+3) + OS survival benefit (+2) + biomarker-guided/precision (+1) = 13
The final overall survival analysis of JUPITER-06, the Phase III trial of first-line toripalimab plus paclitaxel/cisplatin (TP) versus placebo + TP in 514 patients with treatment-naive advanced esophageal squamous-cell carcinoma (ESCC), confirms a durable survival benefit: median OS 17.7 vs 12.9 months (HR 0.72, 95% CI 0.58–0.88, P=0.002), with 3-year OS of 29.7% vs 19.9%. The more important message is biomarker-driven. Neither PD-L1 expression nor conventional TMB correlated with OS benefit; instead, two prespecified genomic tools — copy-number-corrected TMB (ccTMB) and the esophageal cancer genome-based immuno-oncology classification (EGIC) — robustly stratified long-term survivors. Exploratory analysis of 486 sequenced tumors linked loss-of-function SWI/SNF alterations to improved OS and gain-of-function cell-cycle/WNT alterations to reduced benefit, nominating CDK4/6 and PORCN inhibitors as rational combination partners to overcome resistance.
Post angle: In ESCC, the immunochemotherapy survival story is now mature — but the headline is that genomics (ccTMB + EGIC) may finally out-predict PD-L1 for who benefits. #GIOnc #EsophagealCancer #PrecisionMedicine #ImmunOnc